The Federal Joint Committee (G - BA) specified two appropriate comparator therapies according to the approval status: Treatment - naive patients, i.e. patients who had not been treated for HIV before, were to receive
efavirenz in combination with tenofovir and emtricitabine or in combination with abacavir and lamivudine.
Concomitant administration
of efavirenz has been found to reduce plasma levels of levonorgestrel (AUC) by around 50 %.
People who were
taking efavirenz (an HIV antiretroviral medication) took either valerian or a placebo nightly one hour before sleep for four weeks.
Each day, half the volunteers received one pill
containing efavirenz and another containing abacavir and lamivudine.
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline)
with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
Overall, there is an indication of a lesser benefit of the elvitegravir fixed combination versus
the efavirenz combination for treatment - naive patients.
Regarding deaths (outcome «mortality»), there was no statistically significant difference between the elvitegravir fixed combination and
the efavirenz combination.
The other volunteers got tenofovir instead of
the efavirenz, as well as the abacavir - lamivudine pill.
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA - 824 with concomitant lopinavir - ritonavir,
efavirenz, or rifampin.
Specific targets are Transplantation / immunosuppression (cyclosporin, tacrolimus, MMF), Oncology (paclitaxel, docetaxel, tamoxifen), Pain (morphine, tramadol), Psychiatry (antidepressants, antipsychotics), HIV (
efavirenz, nevirapine) and Anticoagulation (coumarins).